科学家发现可以检测多种癌症的血液标记物

2016-10-24 佚名 生物谷

2016年10月24日讯 /生物谷BIOON/ --胰腺癌的早期症状相对不明显,经常导致癌细胞扩散到其他器官之后才被发现。为了改善胰腺癌病人的预后,开发早期胰腺癌检测方法变得非常重要。为了实现这一目标,来自日本的科学家们在血液中发现了一些蛋白能够加强对胰腺癌的检测。结合传统的生物标记物,能够实现对早期阶段胰腺癌的诊断,这在之前是非常困难的。为了发现可以用于胰腺癌检测的生物标记物,研究人员决定对已经


2016年10月24日讯 /生物谷BIOON/ --胰腺癌的早期症状相对不明显,经常导致癌细胞扩散到其他器官之后才被发现。为了改善胰腺癌病人的预后,开发早期胰腺癌检测方法变得非常重要。为了实现这一目标,来自日本的科学家们在血液中发现了一些蛋白能够加强对胰腺癌的检测。结合传统的生物标记物,能够实现对早期阶段胰腺癌的诊断,这在之前是非常困难的。

为了发现可以用于胰腺癌检测的生物标记物,研究人员决定对已经报道过在胰腺癌组织中高表达的基因进行分析。随后他们利用两种类型的蛋白质组学方法检测了大量临床样本,分析候选基因表达的蛋白在胰腺癌病人和健康人血液中的变化情况。最终在130个候选蛋白中找到23个变化显著的蛋白质。

研究人员使用质谱技术和定量蛋白组学技术对这些胰腺癌候选标记物进行了证实。为了更加高效地对大量临床样本进行分析,他们还开发了一种自动分析系统,对65名健康人和38名早期胰腺癌患者血浆中的候选蛋白进行了比对,发现IGFBP2和IGFBP3这两种蛋白在早期胰腺癌患者体内存在显著变化。除此之外,研究人员借助这两个生物标记物在15名病人中诊断出12名早期胰腺癌患者,这些病人在用另外一种叫做CA19-9的标记物进行诊断时呈阴性结果。

研究人员还发现IGFBP2和IGFBP3对于胃癌,胆囊癌,结直肠癌,十二指肠癌以及肝细胞癌的筛查也十分有效。

癌症早发现能够为实现手术完全治愈癌症提供更好的机会,因此研究人员希望这些诊断标记物的发现能够帮助提高病人的预后。相关研究结果发表在国际学术期刊PLOS ONE上。

原始出处

Toshihiro Yoneyama,Sumio Ohtsuki ,Kazufumi Honda,Makoto Kobayashi,Motoki Iwasaki et al.Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.PLOS ONE.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-25 蓬莱阁

    受教了希望可以早日应用于临床

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-25 drmike

    之前也想研究一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1904451, encodeId=79c1190445159, content=<a href='/topic/show?id=b8aa619690e' target=_blank style='color:#2F92EE;'>#标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61969, encryptionId=b8aa619690e, topicName=标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon May 29 21:56:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082305, encodeId=a777208230594, content=<a href='/topic/show?id=737789285f1' target=_blank style='color:#2F92EE;'>#血液标记物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89285, encryptionId=737789285f1, topicName=血液标记物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu Sep 28 11:56:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802350, encodeId=5501180235068, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Jul 31 07:56:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151132, encodeId=106015113220, content=受教了希望可以早日应用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2291960840, createdName=蓬莱阁, createdTime=Tue Oct 25 14:55:05 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150960, encodeId=7ddc15096086, content=之前也想研究一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161003/IMG57F1CE4724D2E2574.jpg, createdBy=c2eb1960303, createdName=drmike, createdTime=Tue Oct 25 00:18:11 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150894, encodeId=8ecd150894cd, content=关注着,谢谢,希望人类早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87421705485, createdName=1de8ed50m80(暂无匿称), createdTime=Mon Oct 24 20:23:20 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-24 1de8ed50m80(暂无匿称)

    关注着,谢谢,希望人类早日攻克癌症

    0

相关资讯

薄荷提取物薄荷素油,“死不了的癌症”的克星

近日,来自比利时的一项新的临床研究显示,薄荷提取物薄荷素油可以用于肠易激综合症的解痉剂。 肠易激综合征(IBS)目前认为是一种肠功能紊乱性疾病。临床上以腹痛、腹胀、排便习惯改变和大便性状异常等症候群为主要特征,常呈慢性间歇发作,经检查排除器质性疾病。过去常用结肠功能紊乱、结肠过敏、痉挛性结肠炎、粘液性结肠炎等命名,近年来统称为肠易激综合征。 肠易激综合征起病隐匿,症状反复发作或慢性迁延,病

Nat Med:重磅!科学家发现阻断癌症扩散的新方法

日前,一项刊登在国际杂志Nature Medicine上的研究报告中,来自麦吉尔大学健康中心和伦敦癌症研究所的研究人员通过联合研究发现,某些癌细胞能够从成熟的血管中抽取血液来促进其继续生长扩散,相关研究或可帮助研究者后期开发新型疗法来改善结肠癌患者的生命及预后情况,研究者还希望能够继续深入研究理解结肠癌扩散的机制,从而为更早地开发出有效阻断癌症扩散的新型靶向性疗法提供思路。通过外科手术通常就能移除

美国副总统拜登提交报告介绍癌症“登月计划”进展

美国副总统乔-拜登周三表示旨在实现治愈癌症目的的癌症“登月计划”在即将过去的这一年中取得了实质进展,虽然美国目前正在进行总统大选,但是政府还有更多工作需要去做。拜登副总统对聚集在美国波士顿的几百名健康医疗专家和研究人员发表了讲话,这名现年73岁的民主党人,在今年一月份巴拉克奥巴马总统在他任内最后一年的国情咨文中提出癌症“登月计划”以后,一直致力于这项工作,由他主持领导的“癌症登月”特别工作小组参

新“分子时钟”预测癌症更近一步

日前,中国科学院上海生命科学研究院计算生物学研究所与英国伦敦大学学院的研究人员在《基因组生物学》杂志上合作发表的一项最新研究成果表明,生命周期中细胞分裂导致的DNA分子变异积累可被用于癌症发生风险的预测。 组织细胞的分裂速度与该组织的癌症发生风险高度相关。研究人员利用计算建模方法设计了一个“分子时钟”,并利用它对个体特定组织生命周期中细胞分裂的次数进行估算。他们同时针对一种只在DNA特定序

PLoS ONE:烟草烟雾引发癌症再添新证据

近日,刊登在国际杂志PLoS ONE上的一项研究报告中,来自肯塔基大学的研究人员通过研究阐明了一种新方法,即烟草烟雾能够促进肺癌的发生,研究者发现,烟草烟雾或许能够抑制DNA的核苷酸切除修复(NER)过程,从而导致肺癌的发生。烟草烟雾中的很多成分都是能够损伤DNA的致癌物,这种损伤能够被DNA修复过程所移除从而就能够抑制机体遗传性突变的产生,诸如核苷酸切除修复等DNA修复过程对于阻断诱发肺癌发生的